Active, not recruitingPhase 2NCT06247735
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kowa Research Institute, Inc.
- Principal Investigator
- Andre Belous, MD, PhDKowa Pharma Development Co.
- Intervention
- K-808 (Dose A)(drug)
- Enrollment
- 46 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- UA Thomas D. Boyer Liver Institute, Tucson, Arizona, United States
- Southern California Research Center - Coronado, Coronado, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Velocity Clinical Research, Santa Ana, California, United States
- Peak Gastroenterology Associates Colorado Springs, Colorado Springs, Colorado, United States
- University of Florida Hepatology Research at CTRB, Gainesville, Florida, United States
- Florida Research Institute, Lakewood Rch, Florida, United States
- University of Miami Leonard M. Miller School of Medicine, Miami, Florida, United States
- Springfield Clinic, Springfield, Illinois, United States
- Mercy Medical Center - Mcauley Plaza, Baltimore, Maryland, United States
- CommonSpirit Health Research Institute, Omaha, Nebraska, United States
- New York University Hepatology Associates, New York, New York, United States
- Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- Einstein Medical Center, Philadelphia, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06247735 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta